Dr. Michael Cox

Biography

 Dr. Michael Cox, Pharm.D., serves as Senior Director, Clinical Development and Medical Affairs. Dr Cox has been involved in the product launches and life cycle management of numerous oncology products including radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®) cetuximab (Erbitux®), denosumab (XGEVA®) and darbepoetin alfa (Aranesp®). Dr. Cox joined Loxo Oncology from Bayer Consumer Care AG, Basel, Switzerland where he served as Medical Affairs Early Pipeline Lead, Oncology for Region Europe/Canada and Emerging Markets. Prior to Bayer, he held global medical affairs positions at Merck KGaA, Darmstadt, Germany and Amgen, Inc., Thousand Oaks, California. Dr. Cox received his Pharm.D. from Ohio Northern University and a MHSc in Clinical Research from Duke Unviersity’s School of Medicine. Dr. Cox completed pharmacy practice residencies at Mission Hospitals in Asheville, North Carolina and the University of Pittsburgh Cancer Institute – University of Pittsburgh Medical Cancer, Pittsburgh, Pennsylvania. He completed a medical oncology/clinical drug development fellowship in the Clinical Pharmacology Section, Center for Cancer Research at the National Cancer Institute, Bethesda, Maryland. He is a Board Certified Oncology Pharmacist.  

Research Interest

  Pharmacology,medical oncology/clinical drug development